European Injectable Drug Delivery Market estimated worth $207.3 Billion by 2020

1
MarketsandMarkets Presents
European Injectable Drug Delivery Market worth
207.3 Billion by 2020
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
2
The report European Injectable Drug Delivery
Market by Type (Device, Formulation), Therapeutic
(Hormonal, Oncology), Usage Pattern (Curative
Care, Immunization), Administration (Skin,
Musculoskeletal), End User (Hospital, Home care
Setting) - Forecast to 2020, provides a detailed
overview of the major drivers, restraints,
challenges, opportunities, current market trends,
and strategies impacting the European injectable
drug delivery market along with estimates and
forecasts of the revenue and market share
analysis. Browse 230 market data tables 43
figures 247 pages and in-depth TOC on "European
Injectable Drug Delivery Market Download The
PDF Brochure_at_ http//www.marketsandmarkets.com/pdf
download.asp?id1205 The European Injectable
Drug Delivery market is expected to reach 207.3
Billion by 2020 from 114.7 Billion in 2015,
growing at a CAGR of 12.6 from 2015 to 2020.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
3
Injectable drug delivery offers a promising
alternative for the delivery of drugs that are
ineffective when administered orally. Injectable
drug delivery is aimed to maximize patient
compliance and reduce the frequency of dosage
administration without compromising the
effectiveness of the treatment. Speak to
Analyst_at_ http//www.marketsandmarkets.com/speaktoa
nalyst.asp?id1205 The report segments the
European injectable drug delivery market on the
basis of types, therapeutic applications, usage
patterns, modes of administration, end users, and
regions. On the basis of type, the formulations
segment is expected to account for the largest
share in 2015, closely followed by the devices
segment. The formulations segment is expected to
grow at the highest CAGR during the forecast
period, owing to the rising prevalence of chronic
diseases, increase in demand of self-injection
devices, growth of the biologics market,
technological advancements, emphasis on
innovation of formulations, and benefits such
high efficacy and reduced side effects offered by
formulations. The formulations market is further
segmented into conventional drug delivery
formulations, novel drug delivery formulations,
and long-acting injection formulations. The
devices market is further segmented into
conventional injection devices, self-injections,
and other devices.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
4
On the basis of therapeutic application, the
European injectable drug delivery market is
segmented into autoimmune diseases, hormonal
disorders, oncology, orphan diseases, and other
therapeutic applications. On the basis of usage
pattern, the market is segmented into curative
care, immunization, and others. On the basis of
mode of administration, the European injectable
drug delivery market is segmented into skin,
organs, central nervous system, and
circulatory/musculoskeletal system. On the basis
of end user, the market is segmented into
hospitals/clinics, home care settings, research
laboratories, pharma and biotech companies, and
other end users.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
5
Geographically, the market is dominated by
Germany, followed by France. Germany is expected
to account for the largest share of the European
injectable drug delivery market in 2015, with the
highest growth rate during the forecast
period. Key players in the European injectable
drug delivery market include Becton, Dickinson
and Company (U.S.), Baxter International Inc.
(U.S.), Gerresheimer AG (Germany), Pfizer Inc.
(U.S.), Schott AG (Germany), Sandoz,(Germany)
Teva Pharmaceutical Industries Ltd. (Israel), and
Eli Lilly and Company (U.S.).
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
6
About MarketsandMarkets MarketsandMarkets
provides quantified B2B research on 30,000 high
growth niche opportunities/threats which will
impact 70 to 80 of worldwide companies
revenues. Currently servicing 5000 customers
worldwide including 80 of global Fortune 1000
companies as clients. Almost 75,000 top officers
across eight industries worldwide approach
MarketsandMarkets for their painpoints around
revenues decisions.   Our 850 fulltime analyst
and SMEs at MarketsandMarkets are tracking
global high growth markets following the "Growth
Engagement Model GEM". The GEM aims at
proactive collaboration with the clients to
identify new opportunities, identify most
important customers, write "Attack, avoid and
defend" strategies, identify sources of
incremental revenues for both the company and its
competitors. MarketsandMarkets now coming up
with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies,
innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets is
determined to benefit more than 10,000 companies
this year for their revenue planning and help
them take their innovations/disruptions early to
the market by providing them research ahead of
the curve.   MarketsandMarketss flagship
competitive intelligence and market research
platform, "RT" connects over 200,000 markets and
entire value chains for deeper understanding of
the unmet insights along with market sizing and
forecasts of niche markets.   
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-injectable-drug-delivery-market-1205.html
7
Contact Us
Mr. Rohan MarketsandMarkets 701 Pike Street
Suite 2175, Seattle, WA 98101, United States
Tel [phone] Email sales_at_marketsandmarket
s.com MarketsandMarkets Bloghttp//www.marketsan
dmarkets.comhttp//twitter.com/marketsmarkets htt
p//www.linkedin.com/company/marketsandmarkets